Journal of Proteomics, Journal Year: 2024, Volume and Issue: 310, P. 105335 - 105335
Published: Oct. 20, 2024
Language: Английский
Journal of Proteomics, Journal Year: 2024, Volume and Issue: 310, P. 105335 - 105335
Published: Oct. 20, 2024
Language: Английский
Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13
Published: Feb. 19, 2025
Extracellular vesicles (EVs) are nano-sized, membranous structures secreted by cells into the extracellular space, have attracted considerable attention in field of biosciences for their role intercellular communication various physiological and pathological processes. Their ubiquitous presence bodily fluids cell-specific characteristics make them promising candidates as biomarkers. Additionally, ability to transport biological therapeutics across different barriers specific target underscores significant translational potential diagnostic therapeutic purposes. Significant progress has been achieved translation EVs research clinical applications, however, challenges persist large-scale production EVs, particularly areas scalable manufacturing, efficient isolation methods, drug loading techniques, advanced characterization technology. This review critically examines complex processes involved biogenesis explores recent developments production. By synthesizing knowledge from these fields, this aims provide a holistic perspective on evolving landscape its underscoring both accomplishments obstacles that lie ahead fully realizing biomedicine.
Language: Английский
Citations
1Expert Review of Hematology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 26, 2025
Acute myeloid leukemia (AML) cells exhibit a profound capacity for resistance to conventional chemotherapeutic agents, posing substantial challenge existing therapeutic paradigms. Interestingly, this happens in the face of luxuriant proliferation leukemic blasts peripheral blood. This paradox concurrent proliferative activity and cellular quiescence underscores complex biological phenomenon that is intricately mediated by AML-derived Extracellular vesicles (EVs). An extensive literature review search was done on Pubmed/Scopus/Web Sciences databases identify studies published between 2013 2024 elucidating demonstrating effect EVs, Microvesicles (MVs) Exosomes (Exos) regulating normal dysregulated bone marrow (BM) niche. The delves into understanding molecular mechanisms underlying dual behavior AML - quiescence, with special focus role EVs their subtypes viz. Exos MVs establishing discrete BM microenvironment subversive chemotherapy. It offers novel perspective intricate interplay microenvironment, implications interventions targeting persistence drug resistance.
Language: Английский
Citations
0Diseases, Journal Year: 2025, Volume and Issue: 13(3), P. 75 - 75
Published: March 3, 2025
Pseudoarthrosis—the failure of normal fracture healing—remains a significant orthopedic challenge affecting approximately 10–15% long bone fractures, and is associated with pain, prolonged disability, repeated surgical interventions. Despite extensive research into the pathophysiological mechanisms healing, diagnostic approaches remain reliant on clinical findings radiographic evaluations, little innovation in tools to predict or diagnose non-union. The present review evaluates current understanding genetic biological basis pseudoarthrosis highlights future directions. Recent studies have highlighted potential specific molecules markers serve as predictors unsuccessful healing. Alterations mesenchymal stromal cell (MSC) function, including diminished osteogenic increased cellular senescence, are central pathogenesis. Molecular analyses reveal suppressed morphogenetic protein (BMP) signaling elevated levels its inhibitors, such Noggin Gremlin, which impair regeneration. Genetic uncovered polymorphisms BMP, matrix metalloproteinase (MMP), Wnt pathways, suggesting predisposition Additionally, differences between atrophic hypertrophic pseudoarthrosis, variations vascularity inflammatory responses, emphasize need for targeted management. Emerging biomarkers, circulating microRNAs (miRNAs), cytokine profiles, blood-derived MSCs, other (B7-1 PlGF-1), contribute early detection at-risk patients personalized therapeutic approaches. Advancing our underpinnings essential development innovative strategies.
Language: Английский
Citations
0BMC Public Health, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 22, 2025
Language: Английский
Citations
0Journal of Proteomics, Journal Year: 2024, Volume and Issue: 310, P. 105335 - 105335
Published: Oct. 20, 2024
Language: Английский
Citations
2